The IPO sets Denali up to push drugs against Alzheimer’s and Parkinson’s diseases through early clinical trials.
Survival in patients who received eryaspase on top of low-dose cytarabine was no longer than that for the group that just got chemotherapy alone.
AZ research exec Johnson jumps to Goldfinch, Human Longevity undergoes C-suite earthquake, Biogen poaches Takeda exec as CIO.
Synlogic and Ginkgo Bioworks have inked a deal to develop treatments for liver and neurological disease by targeting the gut.
Gilead has made a bolt-on acquisition of Cell Design with an eye to the future of CAR-T.
Orbimed is one of the biggest backers of life science companies in the world with $14 billion in asset management, but today its founder, Sam Isaly, has left…
In this week's EuroBiotech Report, U.K. sector deal fizzles as hype hits reality, Idorsia gets $230 million, Cellectis names CMO and more.
In our EuroBiotech roundup this week, Atox raises $30 million, Bluebird inks CAR-T deal and Advicenne IPO raises €27 million.
Juno Therapeutics, which dumped its lead CAR-T program in March, has inked license agreements with Eli Lilly, OncoTracker and Fred Hutch.
SAGE-217 triggered near-immediate, fairly durable improvements in patients with major depressive disorder.